April 25th 2024
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms
April 12th 2024Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.
Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD
April 12th 2024Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.
Safety and Access Considerations: Topical Ruxolitinib Review
April 12th 2024Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.
Expert Insights: Unmet Needs in Topical Treatment for Atopic Dermatitis
April 12th 2024Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.
Expanding on Atopic Dermatitis Triggers and Comorbidities, and Advancements
April 5th 2024Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.
Understanding The Heterogenous Nature of Atopic Dermatitis
April 5th 2024Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.
The AD Journey of a Construction Worker: Insights from a 38-Year-Old Caucasian Male
April 5th 2024Alexandra Golant, MD, presents the case of a 38-year-old Caucasian male construction worker, diagnosed with moderate AD at age 15, and his treatment history with various interventions and physician referral considerations.
Disease Severity's Influence on Atopic Dermatitis Therapeutic Selection
April 5th 2024Dr. Golant discusses the role of disease severity in her selection of atopic dermatitis treatments, particularly noting the characterization of hand and foot involved patients as often moderate cases, and highlighting the rapid response observed in these areas when treated.